These favorable outcomes substantiate the implication of type 2 cytokines in steering the pathogenesis of PN and endorse the targeting of the IL-4/IL-13 axis as an innovative therapeutic approach for individuals with PN [5]. This evidence concerns the gene IL4 and poikiloderma with neutropenia.